Stetten, Switzerland

Adrian Thaler


Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 10(Granted Patents)


Location History:

  • Stetter, CH (2002)
  • Stetten, CH (2000 - 2012)

Company Filing History:


Years Active: 2000-2012

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovations of Adrian Thaler

Introduction

Adrian Thaler is a notable inventor based in Stetten, Switzerland. He has made significant contributions to the field of peptide synthesis, particularly in the development of pulmonary surfactants. With a total of 3 patents to his name, Thaler's work has implications for both medical and pharmaceutical applications.

Latest Patents

Thaler's latest patents focus on the liquid phase peptide synthesis of KL-4 pulmonary surfactant. The first patent describes improved liquid phase processes for the preparation of the 21-residue protein component, (Lys-Leu)-Lys, of the pulmonary surfactant KL-4. This invention is notable for its amenability to large-scale synthesis. One of the processes employs a method of saponifying an ester, which reduces the inherent racemization of the α-carbon. The second patent reiterates these improvements, emphasizing the efficiency and scalability of the synthesis process.

Career Highlights

Adrian Thaler is currently associated with Ortho Pharmaceutical Corporation, where he continues to innovate in the field of peptide synthesis. His work has garnered attention for its potential to enhance the production of vital medical compounds.

Collaborations

Thaler has collaborated with esteemed colleagues such as Ahmed F Abdel-Magid and Urs Eggmann. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Adrian Thaler's contributions to the field of peptide synthesis are noteworthy and impactful. His innovative approaches to the production of pulmonary surfactants demonstrate his commitment to advancing medical science. Through his patents and collaborations, Thaler continues to influence the landscape of pharmaceutical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…